Lundbeck held its Annual General Meeting on 31 March 2016 at the company's registered office

Valby, Denmark, 31 March 2016 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Directors was adopted and the annual report was approved.

The General Meeting approved not to pay-out dividend.

Lars Rasmussen, Lene Skole, Terrie Curran, Lars Holmqvist and Jesper Ovesen were re-elected to the Board of Directors. Håkan Björklund did not stand for re-election. Immediately after the General Meeting, the Board of Directors elected Lars Rasmussen as Chairman and Lene Skole as Deputy Chairman of the Board of Directors.

The Board of Directors of Lundbeck will hereafter comprise:

• Lars Rasmussen (Chairman)
• Lene Skole (Deputy Chairman)
• Terrie Curran
• Lars Holmqvist
• Jesper Ovesen
• Mona Elisabeth Elster (employee representative)
• Jørn Møller Mayntzhusen (employee representative)
• Henrik Sindal Jensen (employee representative)

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Jesper Ovesen, Lars Rasmussen and Lars Holmqvist were elected as members of the Audit Committee. Lars Rasmussen, Lene Skole and Terrie Curran were elected as members of the Remuneration Committee. Lars Rasmussen and Lene Skole were elected as member of the Scientific Committee.

The General Meeting approved the remuneration for the Board of Directors for the year 2016.

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.

The proposal of the Board of Directors to adopt the amended "Remuneration Guidelines for the Board of Directors and the Executive Management of H. Lundbeck A/S" was approved.

The proposal to give the Board of Directors authorization to let the company acquire own shares of a total nominal value of up to 10% of the share capital was adopted. 

The Chairman of the General Meeting was authorized to adopt the amendments and register with the Danish Business Authority.

No other business was handled at the Annual General Meeting.

The Board of Directors

Lundbeck contacts

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.

Our approximately 5,300 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated core revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.